Skip to content

Clinical study of Oxaliplatin +5-FU intra-arterial infusion chemotherapy combined with doxorubicin-loaded microsphere embolization for gastric cardia cancer

Safety and efficacy of Oxaliplatin +5-FU intra-arterial infusion chemotherapy combined with drug-eluting microspheres (CalliSpheres) for gastric artery chemoembolization (GACE) in the treatment of gastric cardia cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018480
Enrollment
Unknown
Registered
2018-09-20
Start date
2018-09-21
Completion date
Unknown
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cardia cancer

Interventions

Case series:Oxaliplatin +5-FU intra-arterial infusion chemotherapy combined with doxorubicin-loaded microsphere embolization

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-75 years old, gender is not limited; 2) It is confirmed by histopathological diagnosis that it is a newly diagnosed gastric cancer that cannot be surgically removed; 3) The expected survival period is greater than 3 months; 4) Physical status score ECOG = 1 point; 5) The pregnancy test for women of childbearing age must be negative; or both men and women need to agree to use effective contraception during the treatment period and for the following year.

Exclusion criteria

Exclusion criteria: 1) Can be surgically removed; 2) Poor coagulation function INR>1.5, or anticoagulant therapy or known bleeding disorder; 3) Unstable coronary heart disease or recent myocardial infarction (within one year); 4) Recent infections require antibiotic treatment; 5) Patients with pulmonary insufficiency (MVV%/VC%=50% and FVC%=40%); 6) White blood cells 2 mg / L); 8) AST and / or ALT > 5 times the upper limit of normal; 9) DSA showed that the tumor feeding artery was too slender and the intubation was unsuccessful; the arteriovenous fistula was not expected to be embolized by the microsphere; 10) A comorbid or social environment that can prevent a subject from following a research plan or even endangering patient safety; 11) The patient is accompanied by other primary tumors.

Design outcomes

Primary

MeasureTime frame
disease control rate;Objective response rate;Safety evaluation;

Secondary

MeasureTime frame
QOL scores;

Countries

China

Contacts

Public ContactWu Gang

The First Affiliated Hospital of Zhengzhou University

wuganghenan2004@163.com+86 13938570175

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026